JP2019218375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019218375A5 JP2019218375A5 JP2019150947A JP2019150947A JP2019218375A5 JP 2019218375 A5 JP2019218375 A5 JP 2019218375A5 JP 2019150947 A JP2019150947 A JP 2019150947A JP 2019150947 A JP2019150947 A JP 2019150947A JP 2019218375 A5 JP2019218375 A5 JP 2019218375A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- disease
- compound according
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 2
- WQMQRNCPZFUGID-UHFFFAOYSA-N 2-azaniumyladamantane-2-carboxylate Chemical compound C1C(C2)CC3CC1C(C(O)=O)(N)C2C3 WQMQRNCPZFUGID-UHFFFAOYSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- FHJXLSAWYORMMX-UHFFFAOYSA-N 9-aminobicyclo[3.3.1]nonane-9-carboxylic acid Chemical compound C1CCC2CCCC1C2(N)C(O)=O FHJXLSAWYORMMX-UHFFFAOYSA-N 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000017922 Neurotensin receptor Human genes 0.000 claims 1
- 108060003370 Neurotensin receptor Proteins 0.000 claims 1
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
| EP12008208.6 | 2012-12-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Division JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019218375A JP2019218375A (ja) | 2019-12-26 |
| JP2019218375A5 true JP2019218375A5 (OSRAM) | 2020-05-07 |
| JP7042776B2 JP7042776B2 (ja) | 2022-03-28 |
Family
ID=47355771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Active JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
| JP2019150947A Active JP7042776B2 (ja) | 2012-12-07 | 2019-08-21 | ニューロテンシン受容体リガンド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545697A Active JP6576828B2 (ja) | 2012-12-07 | 2013-12-06 | ニューロテンシン受容体リガンド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10961199B2 (OSRAM) |
| EP (3) | EP2740726A1 (OSRAM) |
| JP (2) | JP6576828B2 (OSRAM) |
| KR (1) | KR102290803B1 (OSRAM) |
| CN (2) | CN109320502B (OSRAM) |
| AU (1) | AU2013354422B2 (OSRAM) |
| BR (1) | BR112015012530B1 (OSRAM) |
| CA (1) | CA2893605C (OSRAM) |
| DK (2) | DK2928870T3 (OSRAM) |
| ES (2) | ES2941629T3 (OSRAM) |
| FI (1) | FI3712131T3 (OSRAM) |
| HU (2) | HUE061839T2 (OSRAM) |
| IL (1) | IL239080B (OSRAM) |
| MX (1) | MX370354B (OSRAM) |
| PL (2) | PL3712131T3 (OSRAM) |
| PT (2) | PT2928870T (OSRAM) |
| RU (1) | RU2671970C2 (OSRAM) |
| SG (2) | SG10201704564QA (OSRAM) |
| WO (1) | WO2014086499A1 (OSRAM) |
| ZA (1) | ZA201503446B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| AU2015273934B2 (en) * | 2014-06-10 | 2020-08-20 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| ES2882634T3 (es) | 2015-11-24 | 2021-12-02 | Transfert Plus Sec | Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| MY200034A (en) | 2017-02-10 | 2023-12-05 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| BR112020001360A2 (pt) | 2017-07-24 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto. |
| JP7608425B2 (ja) | 2019-07-08 | 2025-01-06 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| AU2021364978A1 (en) * | 2020-10-22 | 2023-06-15 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive zirconium complex |
| CA3217024A1 (en) * | 2021-04-23 | 2022-10-27 | Fusion Pharmaceuticals Inc. | Methods for treatment of cancers |
| EP4352044A4 (en) * | 2021-05-13 | 2025-10-22 | Massachusetts Gen Hospital | MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES |
| WO2022261771A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel |
| WO2022261770A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| WO2022266357A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napox |
| WO2023141722A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| JP2025506705A (ja) | 2022-02-18 | 2025-03-13 | フル－ライフ・テクノロジーズ・ホンコン・リミテッド | ニューロテンシン受容体を標的とする化合物および放射性リガンドおよびその使用 |
| KR20250004887A (ko) * | 2022-05-03 | 2025-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 영상화 및 요법 적용을 위한 ntsr 표적화 제제의 개발 |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
| WO2025144920A1 (en) * | 2023-12-28 | 2025-07-03 | Radionetics Oncology, Inc. | Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| JPH11514329A (ja) | 1994-02-18 | 1999-12-07 | マリンクロット・メディカル・インコーポレイテッド | 標識化ペプチド化合物 |
| WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| AU6352296A (en) | 1995-07-20 | 1997-02-18 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| WO1998033531A1 (en) | 1997-02-03 | 1998-08-06 | Mallinckrodt Medical, Inc. | Method for the detection and localization of malignant human tumours |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| EP1194444A2 (en) | 1999-06-24 | 2002-04-10 | BioSynthema Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| WO2005016141A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| US20100111858A1 (en) * | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US8487077B2 (en) * | 2008-09-16 | 2013-07-16 | The Regents Of The University Of California | Simplified one-pot synthesis of [18F]SFB for radiolabeling |
| CN102307904A (zh) | 2008-12-05 | 2012-01-04 | 安吉奥开米公司 | 神经降压素或神经降压素类似物的缀合物及其用途 |
| ES2538002T3 (es) * | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
| WO2011006985A1 (en) | 2009-07-16 | 2011-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en not_active Ceased
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019218375A5 (OSRAM) | ||
| KR101542812B1 (ko) | 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터 | |
| CN101528214B (zh) | 取代的n-酰基苯胺及其使用方法 | |
| RU2015127086A (ru) | Лиганды рецептора нейротензина | |
| JP2014513136A5 (OSRAM) | ||
| JP2010504079A5 (OSRAM) | ||
| JP2019510832A5 (OSRAM) | ||
| IL255261B2 (en) | A combination of an m-tor inhibitor and rad19010 for use in a method of inhibiting tumor growth or producing tumor regression in a subject having a deug-resistant andqor mutant estrogen receptor | |
| JP2009536620A5 (OSRAM) | ||
| JP2021525768A (ja) | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 | |
| WO2015082990A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2006517939A5 (OSRAM) | ||
| JP2004518674A5 (OSRAM) | ||
| JP2010521516A5 (OSRAM) | ||
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| JP2017530163A5 (OSRAM) | ||
| US11224608B2 (en) | Compounds and methods for treating cancer | |
| US20140134274A1 (en) | Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| CN115397820A (zh) | 用于治疗骨髓增生性肿瘤的赖氨酸特异性组蛋白脱甲基化酶抑制剂 | |
| JPWO2020252336A5 (OSRAM) | ||
| JP2002534379A5 (OSRAM) | ||
| KR20160067225A (ko) | 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제 | |
| JP2005513167A5 (OSRAM) |